Legacy Wealth Asset Management LLC lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 12.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 140,837 shares of the company’s stock after selling 20,779 shares during the period. Legacy Wealth Asset Management LLC’s holdings in Takeda Pharmaceutical were worth $1,865,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in TAK. Public Employees Retirement System of Ohio bought a new position in Takeda Pharmaceutical in the 3rd quarter valued at $601,000. Verition Fund Management LLC bought a new position in Takeda Pharmaceutical during the third quarter valued at about $1,533,000. HighTower Advisors LLC increased its holdings in Takeda Pharmaceutical by 199.5% during the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock worth $1,744,000 after buying an additional 81,653 shares during the last quarter. XTX Topco Ltd bought a new stake in Takeda Pharmaceutical in the third quarter worth about $957,000. Finally, Creative Planning boosted its stake in Takeda Pharmaceutical by 46.3% in the third quarter. Creative Planning now owns 157,630 shares of the company’s stock valued at $2,242,000 after acquiring an additional 49,871 shares during the last quarter. 9.17% of the stock is owned by institutional investors.
Takeda Pharmaceutical Stock Down 0.4 %
Takeda Pharmaceutical stock opened at $13.05 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $41.51 billion, a P/E ratio of 22.49, a P/E/G ratio of 0.23 and a beta of 0.51. The firm has a 50 day moving average price of $13.40 and a 200-day moving average price of $13.89. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
- Five stocks we like better than Takeda Pharmaceutical
- P/E Ratio Calculation: How to Assess Stocks
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Compound Interest and Why It Matters When Investing
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is the Nasdaq? Complete Overview with History
- Micron Technology: Riding the AI Wave to Long-Term Growth
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.